Results 31 to 40 of about 14,967 (152)

The Prognostic Impact of Multiple Adverse Events on Long‐Term Mortality Following Acute Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Adverse events after acute myocardial infarction (AMI) are individually associated with poor outcomes, but the prognostic impact of the overlap of different event types occurring sequentially within the same patient remains uncertain.
Kyung Hoon Roh, Yong Hee Kim, Eun Ho Choo, Kwan Yong Lee, Ik Jun Choi, Jong‐Min Lee, Ki‐Dong Yoo, Mahn‐Won Park, Chul Soo Park, Hee‐Yeol Kim, Min Chul Kim, Youngkeun Ahn, Kiyuk Chang   +12 more
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Progress in the clinical effects and adverse reactions of ticagrelor

Thrombosis Journal
Background Ticagrelor is a novel receptor antagonist that selectively binds to the P2Y12 receptor, thereby inhibiting adenosine diphosphate (ADP)-mediated platelet aggregation.
Peng Wei, Xiaoqing Wang, Qiang Fu, Bangming Cao   +3 more
doaj   +1 more source

Pleiotropic Effects of Ticagrelor: Influence on CYP4F2 Gene and Protein Expression in HUVEC and HepG2, and Escherichia coli Bacterial Survival

Drug Design, Development and Therapy, 2022
Ugne Meskauskaite,1 Silvija Andruskeviciute,1 Ieva Ciapiene,1 Agne Giedraitiene,2 Vaiva Lesauskaite,1 Vacis Tatarunas1 1Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania; 2Institute of Microbiology and Virology ...
Meskauskaite U, Andruskeviciute S, Ciapiene I, Giedraitiene A, Lesauskaite V, Tatarunas V   +5 more
doaj  

Ticagrelor Loading on ST-Elevation Myocardial Infarction: Interaction With Prodromal Angina on Infarct Size and Clinical Events

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Introduction: Ticagrelor might reduce infarct size by exerting a more potent antiplatelet effect or by promoting a potential conditioning stimulus in ST-elevation myocardial infarction (STEMI) patients.
João Pedro Faria MD, Pedro Oliveira PhD, André Alexandre MD, David Sá Couto MD, Ricardo Costa MD, Andreia Campinas MD, André Frias MD, Bruno Brochado MD, Raquel Santos MD, João Silveira MD, Severo Torres MD, André Luz MD, PhD, FESC   +11 more
doaj   +1 more source

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Ticagrelor reduces ischemic risk but increases bleeding in patients with prior myocardial infarction. Identification of patients at lower bleeding risk is important in selecting patients who are likely to derive more favorable outcomes versus ...
Giulia Magnani, Diego Ardissino, KyungAh Im, Andrzej Budaj, Robert F. Storey, P. Gabriel Steg, Deepak L. Bhatt, Marc Cohen, Ton Oude Ophius, Assen Goudev, Alexander Parkhomenko, Gabriel Kamensky, Dominick J. Angiolillo, José López‐Sendón, Per Johanson, Eugene Braunwald, Marc S. Sabatine, Marc P. Bonaca   +17 more
doaj   +1 more source

Tumor‐educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation

International Journal of Cancer, EarlyView.
Abstract Tumor‐educated platelets (TEPs) are emerging as a compelling frontier in liquid biopsy, functioning as dynamic, systemic sensors that sequester and process tumor‐derived biomolecules. This interaction imprints an integrated molecular signature of malignancy—spanning the transcriptome, proteome, lipidome, and crucially, the captured genome ...
Whi‐An Kwon, Min‐Kyung Lee, Eunyong Ahn, Heeyeon Kim, Yong Sang Song, Taejin Ahn   +5 more
wiley   +1 more source

Ticagrelor — a legend of modern cardiology

Российский кардиологический журнал
The article presents the evidence on the basis of which the ticagrelor is used in patients with various forms of coronary artery disease, including both acute and chronic.
S. R. Gilyarevsky
doaj   +1 more source

Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75–100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study

Platelets, 2020
Patients treated with ticagrelor and aspirin usually suffer from bleeding events, especially mild bleeding which is one of the main factors reducing patients’ adherence to ticagrelor.
Jiannan Li, Zhaoxue Sheng, Yu Tan, Chen Liu, Peng Zhou, Jinying Zhou, Runzhen Chen, Yi Chen, Li Song, Hanjun Zhao, Hongbing Yan   +10 more
doaj   +1 more source